Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05141669 · ClinicalTrials.gov registry record
Impact of Fingolimod Adherence on Outcomes
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 694
- Enrollment target
NCT05141669: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05141669 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 694 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05141669 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 694 participants
- Enrollment target
Study Summary
This study was a retrospective observational claims data study of commercial and Medicare Advantage with Part D (MAPD) patients initiating fingolimod.
Primary Outcome
Number of Multiple Sclerosis (MS) relapses were reported to estimate the effect of fingolimod adherence on the odds of MS relapse in a 12-month period
Interventions
- DRUG Fingolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 694 participants |
| Start Date | 2020-05-18 |
| Est. Completion | 2020-11-20 |
What the finished NCT05141669 record still lists
NCT05141669 is an observational study that tracks outcomes without assigning an intervention. The registered 694 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Fingolimod is the first listed.
NCT05141669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05141669 about?
NCT05141669 is a clinical study titled "Impact of Fingolimod Adherence on Outcomes". This study was a retrospective observational claims data study of commercial and Medicare Advantage with Part D (MAPD) patients initiating fingolimod.
What is the current status of trial NCT05141669?
This trial is currently completed. The enrollment target is 694 participants. The study started on 2020-05-18. Estimated completion is 2020-11-20.
What interventions are being tested in trial NCT05141669?
The interventions under investigation include: Fingolimod (DRUG).
Who is sponsoring clinical trial NCT05141669?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05417594 · 695 participants · Phase 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- NCT06801834 · 695 participants · Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- NCT07179016 · 693 participants · NA
Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI